Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

Inclusion criteria: * Histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy, or for whom no standard therapy exists, or who might benefit from treatment with carboplatin * A minimum of 4 weeks since the last treatment with chemotherapy * WHO Performance Status 0 (able to carry out all normal activity without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work) * Age ≥ 18 * Adequate hematological parameters * No major impairment of renal or hepatic function * Written informed consent obtained Exclusion criteria: * Major surgery less than 4 weeks prior to study entry and/or not fully recovered from surgery * Chemotherapy or investigational compound less than 4 weeks prior to study entry, or planned while participating in the study * Prior administration of an epothilone * Hypersensitivity to carboplatin. Patients resistant to carboplatin are not recommended to enter the trial * Radiotherapy (RT) less than 4 weeks prior to study entry (except for palliative therapy of distant metastases), or planned RT while participating in the study * Diarrhea within 7 days prior to start of treatment. Unresolved bowel obstruction * Peripheral neuropathy \> Grade 1 (mild) * Symptomatic brain metastases * Colostomy Other protocol-defined inclusion/exclusion criteria may apply